Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Sökning: onr:"swepub:oai:DiVA.org:uu-456145" > Selpercatinib in RE...

1 av 1
Föregående post
Nästa post
Till träfflistan

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN) : a retrospective analysis of patients treated through an access program

Illini, Oliver (författare): Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Floridsdorf, Brunner Str 68, A-1210 Vienna, Austria.

Hochmair, Maximilian Johannes (författare): Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Floridsdorf, Brunner Str 68, A-1210 Vienna, Austria.

Fabikan, Hannah (författare): Karl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Vienna, Austria.

visa fler...

Weinlinger, Christoph (författare): Karl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Vienna, Austria.

Tufman, Amanda (författare): LMU Munchen, Klinikum Univ Muenchen, Med Klin & Poliklin, Mitglied Deutsch Zentrums Lungenforsch, CPC M, Munich, Bayern, Germany.

Swalduz, Aurelie (författare): Ctr Leon Berard, Lyon, France.

Lamberg, Kristina (författare): Uppsala universitet,Lung- allergi- och sömnforskning,Uppsala Univ Hosp, Sweden

Hashemi, Sayed M. S. (författare): Vrije Univ Amsterdam, Med Ctr, Amsterdam UMC, Canc Ctr Amsterdam, Amsterdam, Netherlands.,Department of Pneumology, Ordensklinikum Elisabethinen Linz, Linz, Austria

Huemer, Florian (författare): Ludwig Boltzmann Inst Lung Hlth, Dept Resp Care, Klin Penzing, Vienna, Austria.

Vikström, Anders (författare): Linkoping Univ Hosp, Pulm clin, Linkoping, Sweden.,Region Östergötland, Lungmedicinska kliniken US

Wermke, Martin (författare): Tech Univ Dresden, Med Fac C G Carus, NCT UCC Early Clin Trial, Unit Dresden, Dresden, Germany.

Absenger, Gudrun (författare): Med Univ Graz, Dept Oncol, Graz, Austria.

Addeo, Alfredo (författare): Univ Hosp Geneva, Oncol Dept, Geneva, Switzerland.

Banerji, Shantanu (författare): Univ Manitoba, Res Inst Oncol & Hematol, Canc Care Manitoba, Winnipeg, MB, Canada.

Calles, Antonio (författare): Univ Gregorio Maranon, Hosp Gen, Med Oncol Dept, Madrid, Spain.

Clarke, Stephen (författare): Royal North Shore Hosp, Med Oncol Unit, St Leonards, NSW, Australia.

Di Maio, Massimo (författare): Univ Turin, Dept Oncol, Turin, Italy.;Ordine Mauriziano Hosp, Med Oncol, Turin, Italy.

Durand, Alice (författare): Univ Lyon, France Univ Claude Bernard Lyon 1, Hosp Civils Lyon, Canc Inst Lyon,Louis Pradel Hosp,Resp Dept, Lyon, France.

Duruisseaux, Michael (författare): Hosp Civils Lyon, Canc Inst, Louis Pradel Hosp, Resp Dept, Lyon, France.;Canc Res Ctr Lyon, Oncopharmacol Lab, Lyon, France.;Univ Lyon, Univ Claude Bernard Lyon 1, Lyon, France.

Itchins, Malinda (författare): Royal North Shore Hosp, Med Oncol Unit, St Leonards, NSW, Australia.

Kääränien, Okko-Sakari (författare): Kuopio Univ Hosp, Ctr Canc, Kuopio, Finland.

Krenn, Florian (författare): LKH Hochsteiermark Standort Leoben, Abt Lungenkrankheiten, Leoben, Austria.

Laack, Eckart (författare): Studiengesellschaft Hamatoonkol Hamburg, Hamburg, Germany.

de Langen, Adrianus Johannes (författare): Netherlands Canc Inst, Amsterdam, Netherlands.

Mohorcic, Katja (författare): Univ Clin Goln, Med Oncol Unit, Golnik, Slovenia.

Pall, Georg (författare): Univ Innsbruck Hosp, Dept Internal Med V Hematol Oncol, Innsbruck, Austria.

Passaro, Antonio (författare): European Inst Oncol IRCCS, Div Thorac Oncol, Milan, Italy.

Prager, Gerald (författare): Comprehens Canc Ctr Vienna, Dept Med I, Vienna, Austria.

Rittmeyer, Achim (författare): LKI Lungenfachklin Immenhausen, Dept Thorac Oncol, Immenhausen, Germany.

Rothenstein, Jeffrey (författare): R.S. McLaughlin Durham Regional Cancer Center at Lakeridge Health, Adjunct Assistant Professor Queen’s University, Ontario, Canada

Schumacher, Michael (författare)

Woell, Ewald (författare): Department Internal Medicine, St. Vinzenz Krankenhaus Betriebs GmbH, Sanatoriumstr. 43, 6511 Zams, Austria

Valipour, Arschang (författare): Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna

visa färre...

Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Floridsdorf, Brunner Str 68, A-1210 Vienna, Austria Karl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Vienna, Austria. (creator_code:org_t)

2021-06-11
2021
Engelska.
Ingår i: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. - : Sage Publications. - 1758-8340 .- 1758-8359. ; 13

Relaterad länk:: https://doi.org/10.1...; visa fler...; https://uu.diva-port... (primary) (Raw object); https://journals.sag...; https://liu.diva-por... (primary) (Raw object); https://urn.kb.se/re...; https://doi.org/10.1...; https://urn.kb.se/re...; visa färre...

Tidskriftsartikel (refereegranskat)

Abstract Ämnesord

Stäng

Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their efficacy in the real-world setting is unknown. Methods: A retrospective efficacy and safety analysis was performed on data from RET fusion-positive NSCLC patients who participated in a selpercatinib access program (named patient protocol) between August 2019 and January 2021. Results: Data from 50 patients with RET fusion-positive advanced NSCLC treated with selpercatinib at 27 centers in 12 countries was analyzed. Most patients were Non-Asian (90%), female (60%), never-smokers (74%), with a median age of 65 years (range, 38-89). 32% of the patients had known brain metastasis at the time of selpercatinib treatment. Overall, 13 patients were treatment-naive, while 37 were pretreated with a median of three lines of therapy (range, 1-8). The objective response rate (ORR) was 68% [95% confidence interval (CI), 53-81] in the overall population. The disease control rate was 92%. The median progression-free survival was 15.6 months (95% CI, 8.8-22.4) after a median follow-up of 9 months. In patients with measurable brain metastases (n = 8) intracranial ORR reached 100%. In total, 88% of patients experienced treatment-related adverse events (TRAEs), a large majority of them being grade 1 or 2. The most common grade > 3 TRAEs were increased liver enzyme levels (in 10% of patients), prolonged QTc time (4%), abdominal pain (4%), hypertension (4%), and fatigue/asthenia (4%). None of patients discontinued selpercatinib treatment for safety reasons. No new safety concerns were observed, nor where there any treatment-related death. Conclusions: In this real-world setting, the selective RET-inhibitor selpercatinib demonstrated durable systemic and intracranial antitumor activity in RET fusion-positive NSCLC and was well tolerated.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)

Nyckelord

non-small cell lung cancer (NSCLC)
real-world data
RET gene fusions
selpercatinib
targeted therapy
tyrosine kinase inhibitor (TKI)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 1
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Urologi och njur ...

Artiklar i publikationen: THERAPEUTIC ADVA ...

Av lärosätet: Uppsala universitet; Linköpings universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se